<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381832</url>
  </required_header>
  <id_info>
    <org_study_id>ARC-6</org_study_id>
    <nct_id>NCT04381832</nct_id>
  </id_info>
  <brief_title>Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer</brief_title>
  <acronym>ARC-6</acronym>
  <official_title>A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor
      activity and safety of AB928-based combination therapy in participants with metastatic
      castrate resistant prostate cancer (mCRPC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has several treatment arms and each treatment arm has 2 stages. During Stage 1 -
      AB928 plus zimberelimab alone, AB928 plus zimberelimab with or without a standard of care
      treatment (enzalutamide or docetaxel), or AB928 plus AB680 with or without zimberelimab will
      be administered to participants with mCRPC.

      During Stage 2 - Additional participants with mCRPC may receive an AB928-based combination
      therapy evaluated in Stage 1 or, a standard of care treatment.

      A pharmacokinetic (PK) Sub-Study (AB928 plus zimberelimab) will be conducted separately.

      Treatment may continue until unacceptable toxicity or progressive disease, or other reasons
      specified in the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR), defined as the composite proportion of participants with a PSA and/or radiographic complete and partial response determined by the investigator according to the Prostate Cancer Working Group 3 (PCWG3) criteria</measure>
    <time_frame>From study enrollment until participant discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (approximately 1 year)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of AEs and serious adverse events (SAEs)</measure>
    <time_frame>From first dose date to 90 days after the last dose (approximately 1 year)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a PSA response defined as the proportion of participants with a confirmed PSA decrease from baseline of 50% or more based on two consecutive assessments measured 3 to 4 weeks apart</measure>
    <time_frame>From study enrollment until disease progression or loss of clinical benefit (approximately 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with measurable disease at baseline who achieved a best overall response of CR or PR according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>From study enrollment until disease progression or loss of clinical benefit (approximately 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with measurable disease at baseline who achieved a best overall RECIST response of CR, PR, or SD</measure>
    <time_frame>From study enrollment until disease progression or loss of clinical benefit (approximately 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum/ Plasma Concentration AB928, zimberelimab, and enzalutamide when administered as part of a combination regimen in Stage 1 &amp; 2.</measure>
    <time_frame>Recorded at baseline (enrollment), during the first 5 months of treatment and 3 additional timepoints in the first year of treament. (approximately 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum/Plasma Concentration for AB928 and zimberelimab when administered as part of a combination regimen with docetaxel in Stage 1 &amp; 2.</measure>
    <time_frame>Recorded at baseline (enrollment), during the first 5 months of treatment and 3 additional timepoints in the first year of treatment. (approximately 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum/Plasma Concentration for AB928 and zimberelimab when administered as part of a combination regimen in Stage 1 &amp; 2.</measure>
    <time_frame>Recorded at baseline (enrollment), during the first 5 months of treatment and 3 additional timepoints in the first year of treatment. (approximately 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum/Plasma Concentration for AB928, zimberelimab, and AB680 when administered as part of a combination regimen in Stage 1 &amp; 2.</measure>
    <time_frame>Recorded at baseline (enrollment), during the first 5 months of treatment and 3 additional timepoints in the first year of treatment. (approximately 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum/Plasma Concentration for AB928 and AB680 when administered as part of a combination regimen in Stage 1 &amp; 2.</measure>
    <time_frame>Recorded at baseline (enrollment), during the first 5 months of treatment and 3 additional timepoints in the first year of treatment. (approximately 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with anti-drug antibodies to zimberelimab</measure>
    <time_frame>Recorded at baseline (enrollment), during the first 4 months of treatment, 4 additional timepoints in the first year of treament, and at end of treatment. (approximately 1 year)</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Prostatic Neoplasms, Castration-Resistant</condition>
  <condition>Androgen-Resistant Prostatic Neoplasms</condition>
  <condition>Castration Resistant Prostatic Neoplasms</condition>
  <condition>Prostatic Cancer, Castration-Resistant</condition>
  <arm_group>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab + enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral AB928 in combination with intravenous (IV) zimberelimab and standard oral enzalutamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: enzalutamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive standard oral enzalutamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab + docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral AB928 in combination with IV zimberelimab and standard IV docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive standard dose of IV docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral AB928 in combination IV zimberelimab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab + AB680</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral AB928 in combination with IV zimberelimab and IV AB680</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 and 2: AB928 + AB680</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral AB928 in combination with IV AB680</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: AB928 + zimberelimab PK Sub-Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral AB928 in combination with IV zimberelimab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB928</intervention_name>
    <description>AB928 is an A2aR and A2bR antagonist</description>
    <arm_group_label>Stage 1 and 2: AB928 + AB680</arm_group_label>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab</arm_group_label>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab + AB680</arm_group_label>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab + docetaxel</arm_group_label>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab + enzalutamide</arm_group_label>
    <arm_group_label>Stage 1: AB928 + zimberelimab PK Sub-Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zimberelimab</intervention_name>
    <description>Zimberelimab is an anti-PD-1 antibody</description>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab</arm_group_label>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab + AB680</arm_group_label>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab + docetaxel</arm_group_label>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab + enzalutamide</arm_group_label>
    <arm_group_label>Stage 1: AB928 + zimberelimab PK Sub-Study</arm_group_label>
    <other_name>AB122</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB680</intervention_name>
    <description>AB680 is a Cluster of Differentiation (CD)73 Inhibitor.</description>
    <arm_group_label>Stage 1 and 2: AB928 + AB680</arm_group_label>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab + AB680</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Enzalutamide is an androgen receptor inhibitor</description>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab + enzalutamide</arm_group_label>
    <arm_group_label>Stage 2: enzalutamide</arm_group_label>
    <other_name>Xtandi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel is type of chemotherapy</description>
    <arm_group_label>Stage 1 and 2: AB928 + zimberelimab + docetaxel</arm_group_label>
    <arm_group_label>Stage 2: docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          -  Male participants; age ≥ 18 years

          -  Metastatic castrate-resistant prostate cancer while on anti-androgen treatment with
             castrate levels of testosterone (≤1.7 nmol/L or 50 ng/dL)

          -  Measurable or non-measurable disease as per radiographic evaluation

          -  Participants with measurable disease may require a fresh tumor biopsy at study entry

          -  Performance status of 0 or 1

          -  Life expectancy of at least 3 months

          -  Adequate hematologic and end-organ function

          -  Inclusion Criteria for Participants receiving an enzalutamide-containing treatment

               -  Disease progression after prior treatment with abiraterone

          -  Inclusion Criteria for Participants receiving a docetaxel-containing treatment

               -  Disease progression after prior androgen synthesis inhibitor therapy

          -  Inclusion Criteria for all other Participants

               -  Disease progression after prior androgen synthesis inhibitor treatment and up to
                  2 prior lines of taxane chemotherapy

        General Exclusion Criteria:

          -  Prior treatment with immune checkpoint blockade therapy

          -  Prior anticancer treatment including approved agents, systemic radiotherapy, or
             investigational therapy, within 2-4 weeks prior first study treatment

          -  ECG (Electrocardiogram) result with QTcF ≥480 msec

          -  Prior stem cell or solid organ transplantation

          -  Prior treatment with drugs that stimulate the immune system within 4 weeks prior to
             first study treatment

          -  Prior treatment with drugs that suppress the immune system within 2 weeks prior to
             first study treatment

          -  Received a live, attenuated vaccine within 4 weeks prior to first study treatment, or
             may need to receive a vaccine during study treatment

          -  Presence of metastases in the brain or cancer spreading into the cerebrospinal fluid -
             CSF (leptomeningeal disease)

          -  Prior pulmonary fibrosis, pneumonia, or pneumonitis

          -  Cancer other than prostate within 2 years prior to study entry, except for some
             cancers with a low risk of spreading like non-melanoma skin

          -  Prior treatment with an agent targeting the adenosine pathway

          -  No oral or IV antibiotics within 2 weeks prior to first study treatment

          -  No severe infection within 4 weeks prior to first study treatment

          -  No clinically significant cardiac disease

          -  Inability to swallow oral medications

          -  HIV, Hepatitis B, and C test results negative prior to first study treatment

          -  Exclusion Criteria for Participants receiving an enzalutamide-containing treatment

               -  Prior treatment with docetaxel, cabazitaxel, or other taxane chemotherapy (prior
                  docetaxel [up to 6 cycles] for hormone-sensitive prostate cancer is allowed if
                  the last dose was at least 6 months prior to study treatment initiation)

               -  Prior treatment with enzalutamide or similar therapy other than abiraterone

               -  Active or history of autoimmune disease or immune deficiency

               -  History of severe allergic reactions to antibody therapy

               -  Concomitant use of a medication prohibited by the protocol (including certain
                  transporter substrates as well as known strong CYP3A4 inducers and CYP3A4
                  inhibitors) within 4 weeks prior to and throughout study treatment

          -  Exclusion Criteria for Participants receiving a docetaxel-containing treatment

               -  Prior treatment with docetaxel, cabazitaxel, or other taxane chemotherapy

               -  Active or history of autoimmune disease or immune deficiency

               -  History of severe allergic reactions to antibody therapy

               -  Concomitant use of a medication prohibited by the protocol (including certain
                  transporter substrates as well as known strong CYP3A4 inducers and CYP3A4
                  inhibitors) within 4 weeks prior to and throughout study treatment

          -  Exclusion Criteria for all other Participants

               -  Prior treatment with 3 or more lines of taxane chemotherapy

               -  Active or history of autoimmune disease or immune deficiency

               -  History of severe allergic reactions to antibody therapy

               -  Concomitant use of a medication prohibited by the protocol (including certain
                  transporter substrates as well as known strong CYP3A4 inducers and CYP3A4
                  inhibitors) within 4 weeks prior to and throughout study treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Director</last_name>
    <phone>510-694-6200</phone>
    <email>ClinicalTrialInquiry@arcusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of California, Los Angeles</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>818-995-8044</phone>
      <email>KHILBURN@MEDNET.UCLA.EDU</email>
    </contact>
    <investigator>
      <last_name>Sandy Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>714-456-7005</phone>
      <email>sbereta@hs.uci.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Uchio, MD,FACS, CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>415-353-2051</phone>
    </contact>
    <investigator>
      <last_name>Lawrence Fong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope &amp; Innovation</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
      <phone>562-698-6888</phone>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Merrill Shum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>203-200-2328</phone>
      <email>matthew.piscatelli@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Vijay Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists South</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>941-377-9993</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth Guancial, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists Panhandle</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>850-877-8166</phone>
    </contact>
    <investigator>
      <last_name>Viralkumar Bhanderi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists East</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>561-366-4100</phone>
    </contact>
    <investigator>
      <last_name>Daniel Spitz, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>312-695-1102</phone>
      <email>cancertrials@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>David VanderWeele, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>410-955-8964</phone>
      <email>rlee129@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Carducci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University, Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>212-731-6366</phone>
    </contact>
    <investigator>
      <last_name>David Wise, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>423-698-1844</phone>
    </contact>
    <investigator>
      <last_name>Edward Arrowsmith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>615-320-5090</phone>
    </contact>
    <investigator>
      <last_name>Johanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Sumit Subudhi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates, PS (dba Summit Cancer Centers)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Chaudhry</last_name>
      <phone>855-786-6482</phone>
      <email>chaudhrym@nwrm.com</email>
    </contact>
    <investigator>
      <last_name>Arvind Chaudhry, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>608-265-1700</phone>
      <email>mjs@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Hamid Emamekhoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>506-857-5111</phone>
      <email>MRUDULA.AVILELI@HORIZONNB.CA</email>
    </contact>
    <investigator>
      <last_name>Mahmoud Abdelsalam, MD, CCFP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>905-387-9495</phone>
      <phone_ext>64417</phone_ext>
      <email>cancerclinicaltrials@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Sebastien Hotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal (CHUM) Centre de Recherche</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>27466</phone_ext>
      <email>amal.nadiri.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Fred Saad, MD, FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

